Calcium and Bone Metabolism Indices

Advances in Clinical Chemistry

Volumn 82, Issue , 2017, Pages 1-46

  Song, Lu ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

1,25 Dihydroxyvitamin D; 25 Hydroxyvitamin D; Bone alkaline phosphatase; Bone formation markers; Bone resorption markers; Calcium homeostasis; CTX; FGF23; Hormones regulating calcium homeostasis; Hypercalcemia; Hyperparathyroidism; Hyperphosphatemia; Hypocalcemia; Hypoparathyroidism; Hypophosphatemia; Measurement of 25 hydroxyvitamin D; Measurement of calcium; Measurement of free calcium; Measurement of PTH; Metabolic bone diseases; NTX; Osteocalcin; Osteomalacia; Osteoporosis; P1NP; Paget disease; Phosphate homeostasis; PTH; Regulation of phosphate homeostasis; Renal osteodystrophy; Rickets

Indexed keywords

CALCIUM;

HOMEOSTASIS; HUMAN; METABOLIC BONE DISEASE; METABOLISM;

BONE DISEASES, METABOLIC; CALCIUM; HOMEOSTASIS; HUMANS;

EID: 85028035813     PISSN: 00652423     EISSN: None     Source Type: Book Series    
DOI: 10.1016/bs.acc.2017.06.005     Document Type: Chapter

References (160)

1. Clark, B., Normal bone anatomy and physiology. Clin. J. Am. Soc. Nephrol. 3 (2008), S131–S139.
2. Klemm, K.M., Klein, M.J., Biochemical markers of bone metabolism. McPherson, R.A., Pincus, M.R., (eds.) Henry's Clinical Diagnosis and Management by Laboratory Methods, 22nd ed., 2011, Elsevier Publishing, San Diego, CA, 193.
3. Johnson, J.A., Kumar, R., Renal and intestinal calcium transport: roles of vitamin D and vitamin D-dependent calcium binding proteins. Semin. Nephrol. 14 (1994), 119–128.
4. Hunt, C.D., Johnson, L.K., Calcium requirements: new estimations for men and women by cross-sectional statistical analyses of calcium balance data from metabolic studies. Am. J. Clin. Nutr. 86 (2007), 1054–1063.
5. Blaine, J., Chonchol, M., Levi, M., Renal control of calcium, phosphate, and magnesium homeostasis. Clin. J. Am. Soc. Nephrol. 10 (2015), 1257–1272.
6. El-Hajj Fuleihan, G., Brown, E.M., Parathyroid hormone secretion and action. Rosen, C.J., (eds.) UpToDate, 2014, UpToDate, Waltham, MA (updated: Mar 14, 2014). (Accessed on April 22, 2016).
7. Winter, W.E., Harris, N.S., Calcium biology and disorders. Clarke, W., (eds.) Contemporary Practice in Clinical Chemistry, second ed., 2011, AACC Press, Washington, DC, 506.
8. Fitzpatrick, L., Bilezikian, J.P., Parathyroid hormone: structure, function, and dynamic actions. Seibel, M.J., Robins, S.P., Bilezikian, J.P., (eds.) Dynamics of Bone and Cartilage Metabolism, second ed., 2006, Academic Press, San Diego, CA, 273–291.
9. A. B. Hodsman, D. C. Bauer, D. W. Dempster, L. Dian, D. A. Hanly, S. T. Harris, et al., Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use, Endocr. Rev., 26 (2005), pp. 688–703.
10. Risteli, J., Winter, W., Kleerekoper, M., Risteli, L., Bone and mineral metabolism. Burtis, C.A., Ashwood, E.R., Bruns, D., (eds.) Tietz Textbook of Clinical Chemistry and Molecular Diagnostics, fifth ed., 2012, Elsevier Publishing, San Diego, CA, 1757.
11. D'Souza-Li, L., The calcium-sensing receptor and related diseases. Arq. Bras. Endocrinol. Metabol. 50 (2006), 628–639.
12. Ricardi, D., Brown, E.M., Physiology and pathophysiology of the calcium-sensing receptor in the kidney. Am. J. Phyiol. Renal Physiol. 298:3 (2010), F485–F499.
13. Silver, J., Russell, J., Sherwood, L.M., Regulation by vitamin D metabolites of messenger ribonucleic acid for preproparathyroid hormone in isolated bovine parathyroid cells. Proc. Natl. Acad. Sci. U.S.A. 82 (1985), 4270–4273.
14. 3 of transcription of the pre-proparathyroid hormone gene. Endocrinology 119 (1986), 2864–2866.
15. Silver, J., Naveh-Many, T., Mayer, H., et al. Regulation by vitamin D metabolites of parathyroid hormone gene transcription in vivo in the rat. J. Clin. Invest. 78 (1986), 1296–1301.
16. Almaden, Y., Hernandez, A., Torregrosa, V., Canalejo, A., Sabate, L., Fernandez, C.L., et al. High phosphate level directly stimulates parathyroid hormone secretion and synthesis by human parathyroid tissue in vitro. J. Am. Soc. Nephrol. 9 (1998), 1845–1852.
17. Leicht, E., Biro, G., Mechanisms of hypocalcemia in the clinical form of severe magnesium deficit in the human. Magnes. Res. 5 (1992), 37–44.
18. Favus, M.J., Goltzman, D., Regulation of calcium and magnesium. Rosen, C.J., Compston, J.E., Lian, J.B., (eds.) Primer on the Metabolic Bone Disease and Disorders of Mineral Metabolism, seventh ed., 2008, American Society for Bone and Mineral Research, Washington, DC, 104–108.
19. D'Amour, P., Rakel, A., Brossard, J.H., et al. Acute regulation of circulating parathyroid hormone(PTH) molecular forms by calcium: utility of PTH fragments/PTH(1-84) ratios derived from three generations of PTH assays. J. Clin. Endocrinol. Metab., 91, 2006, 283.
20. Potts, J.T., Juppner, H., Parathyroid hormone: molecular biology regulation. Bilezikian, P., Raisz, L.G., Rodan, G.A., (eds.) Principles of Bone Biology, 1996, Academic Press, San Diego, CA, 325.
21. Habener, J.F., Kemper, B.W., Rich, A., Potts, J.T. Jr., Biosynthesis of parathyroid hormone. Recent Prog. Horm. Res., 33, 1976, 249.
22. Murray, T.M., Rao, L.G., Divieti, P., Bringhurst, F.R., Parathyroid hormone secretion and action: evidence for discrete receptors for the carboxyl-terminal region and related biological actions of carboxyl-terminal region and related biological actions of carboxyl-terminal ligands. Endocr. Rev., 26, 2005, 78.
23. Diaz, R., El-Hajj Fuleihan, G., Brown, E.M., Regulation of parathyroid function. Fray, G.G.S., (eds.) Handbook of Physiology, Section 7: The Endocrine System, 1999, Oxford University Press, New York.
24. Carnevale, V., Dionisi, S., Nofroni, I., Romagnoli, E., Paglia, F., De Geronimo, S., Pepe, J., Clemente, G., Tonnarini, G., Minisola, S., Potential clinical utility of a new IRMA for parathyroid hormone in postmenopausal patients with primary hyperparathyroidism. Clin. Chem. 50 (2004), 626–631.
25. Divieti, P., John, M.R., Jüppner, H., Bringhurst, F.R., Human PTH-(7-84) inhibits bone resorption in vitro via actions independent of the type 1 PTH/PTHrP receptor. Endocrinology 143 (2002), 171–176.
26. Vieira, J.G., Kunii, I., Nishida, S., Evolution of PTH assays. Arq. Bras. Endocrinol. Metabol. 50 (2006), 621–627.
27. Brossard, J.H., Cloutier, M., Roy, L., Lepage, R., Gascon-Barré M., D'Amour, P., Accumulation of a non-(1-84) molecular form of parathyroid hormone (PTH) detected by intact PTH assay in renal failure: importance in the interpretation of PTH values. J. Clin. Endocrinol. Metab. 81 (1996), 3923–3929.
28. John, M.R., Goodman, W.G., Gao, P., Cantor, T.L., Salusky, I.B., Jüppner, H., A novel immunoradiometric assay detects full-length human PTH but not amino-terminally truncated fragments: implications for PTH measurements in renal failure. J. Clin. Endocrinol. Metab. 84 (1999), 4287–4290.
29. Souberbielle, J.C., Roth, H., Fouque, D.P., Parathyroid hormone measurement in CKD. Kidney Int. 77 (2010), 93–100.
30. Uhlig, K., Berns, J.S., Kestenbaum, B., Kumar, R., Leonard, M.B., Martin, K.J., Sprague, S.M., Goldfarb, S., KDOQI US commentary on the 2009 KDIGO clinical practice guideline for the diagnosis, evaluation, and treatment of CKD-mineral and bone disorder (CKD-MBD). Am. J. Kidney Dis. 55 (2010), 773–799.
31. Lopez, M.F., Rezai, T., Sarracino, D.A., Prakash, A., Krastins, B., Athanas, M., et al. Selected reaction monitoring-mass spectrometric immunoassay responsive to parathyroid hormone and related variants. Clin. Chem. 56 (2010), 281–290.
32. Kumar, V., Barnidge, D.R., Chen, L.-S., Twentyman, J.M., Cradic, K.W., Grebe, S.K., et al. Quantification of serum 1-84 parathyroid hormone in patients with hyperparathyroidism by immunocapture in situ digestion liquid chromatography-tandem mass spectrometry. Clin. Chem. 56 (2010), 306–313.
33. Couchman, L., Taylor, D.R., Krastins, B., Lopez, M.F., Moniz, C.F., LC-MS candidate reference methods for the harmonisation of parathyroid hormone (PTH) measurement: a review of recent developments and future considerations. Clin. Chem. Lab. Med. 52 (2014), 1251–1263.
34. Irvin, G.L. 3rd., Dembrow, V.D., Prudhomme, D.L., Operative monitoring of parathyroid gland hyperfunction. Am. J. Surg., 162, 1991, 299.
35. Chapuis, Y., Icard, P., Fulla, Y., et al. Excision under local anesthesia of parathyroid adenomas. Criteria of selection and control of effectiveness. 35 cases. Presse Med., 20, 1991, 2090.
36. Schneider, D.F., Mazeh, H., Sippel, R.S., Chen, H., Is minimally invasive parathyroidectomy associated with greater recurrence compared to bilateral exploration? Analysis of more than 1,000 cases. Surgery, 152, 2012, 1008.
37. Greene, A.B., Butler, R.S., McIntyre, S., et al. National trends in parathyroid surgery from 1998 to 2008: a decade of change. J. Am. Coll. Surg., 209, 2009, 332.
38. Solorzano, C.C., Cameiro-Pla, D.M., Intraoperative parathyroid hormone assays. Carty, S.E., (eds.) UpToDate, 2015, UpToDate, Waltham, MA (updated: Nov 23, 2015). Accessed on May 25, 2016.
39. Wharry, L.I., Yip, L., Armstrong, M.J., et al. The final intraoperative parathyroid hormone level: how low should it go?. World J. Surg., 38, 2014, 558.
40. Wachtel, H., Cerullo, I., Bartlett, E.K., et al. What can we learn from intraoperative parathyroid hormone levels that do not drop appropriately?. Ann. Surg. Oncol., 22, 2015, 1781.
41. Carty, S.E., Worsey, J., Virji, M.A., et al. Concise parathyroidectomy: the impact of preoperative SPECT 99mTc sestamibi scanning and intraoperative quick parathormone assay. Surgery, 122, 1997, 1107.
42. Carty, S.E., Roberts, M.M., Virji, M.A., et al. Elevated serum parathormone level after “concise parathyroidectomy” for primary sporadic hyperparathyroidism. Surgery, 132, 2002, 1086.
43. Winter, W., Kleerekoper, M., Bone and mineral metabolism. Risteli, J., Risteli, L., Burtis, C.A., Ashwood, E.R., Bruns, D., (eds.) Tietz Textbook of Clinical Chemistry and Molecular Diagnostics, fifth ed., 2012, Elsevier Publishing, San Diego, CA, 1765.
44. Pazirandeh, S., Burns, D., Overview of vitamin D. Motil, K.J., Drezner, M.K., (eds.) UpToDate, 2016, UpToDate, Waltham, MA (updated: May, 2016). Accessed on June 5, 2016.
45. Dawson-Hughes, B., Vitamin D deficiency in adults: definition, clinical manifestations, and treatment. Drezner, M.K., Rosen, C.J., (eds.) UpToDate, 2016, UpToDate, Waltham, MA (updated: March, 2016). Accessed on June 5, 2016.
46. B. Dawson-Hughes, S. S. Harris, E. A. Krall, G. E. Dallal, Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older, N. Engl. J. Med. 337 (1997), p.670.
47. Chapuy, M.C., Pamphile, R., Paris, E., et al. Combined calcium and vitamin D3 supplementation in elderly women: confirmation of reversal of secondary hyperparathyroidism and hip fracture risk: the Decalyos II study. Osteoporos. Int., 13, 2002, 257.
48. D. P. Trivedi, R. Doll, K. T. Khaw, Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial, BMJ 326 (2003), p. 469.
49. Sanders, K.M., Stuart, A.L., Williamson, E.J., et al. Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial. JAMA, 303, 2010, 1815.
50. Institute of Medicine, Food and Nutrition Board, Dietary Reference Intakes for Calcium and Vitamin D. 2010, National Academy Press, Washington, DC.
51. Heijboer, A.C., Blankenstein, M.A., Kema, I.P., Buijs, M.M., Accuracy of 6 routine 25-hydroxyvitamin D assays: influence of vitamin D binding protein concentration. Clin. Chem. 58 (2012), 543–548.
52. Farrell, C.J.L., Martin, S., Mcwinnnney, B., et al. State-of-the-art vitamin D assays: a comparison of automated immunoassays with liquid chromatography–tandem mass spectrometry methods. Clin. Chem. 58 (2012), 531–543.
53. Maunsell, Z., Wright, D.J., Rainbow, S.J., Routine isotope-dilution liquid chromatography-tandem mass spectrometry assay for simultaneous measurement of the 25-hydroxy metabolites of vitamins D2 and D3. Clin. Chem. 51 (2005), 1683–1690.
54. Singh, R.J., Taylor, R.L., Reddy, G.S., Grebe, S.K., C-3 epimers can account for a significant proportion of total circulating 25-hydroxyvitamin D in infants, complicating accurate measurement and interpretation of vitamin D status. J. Clin. Endocrinol. Metab. 91 (2006), 3055–3061.
55. Schleicher, R.L., Encisco, S.E., Chaudhary-Webb, M., Paliakov, E., McCoy, L.F., Pfeiffer, C.M., Isotope dilution ultra performance liquid chromatography-tandem mass spectrometry method for simultaneous measurement of 25-hydroxyvitamin D2, 25-hydroxyvitamin D3 and 3-epi-25-hydroxyvitamin D3 in human serum. Clin. Chim. Acta 412 (2011), 1594–1599.
56. Nielson, C.M., Jones, K.S., Chun, R.F., et al. Free 25-hydroxyvitamin D: impact of vitamin D binding protein assays on racial-genotypic associations. J. Clin. Endocrinol. Metab. 101 (2016), 2226–2234.
57. Powe, C.E., Evans, M.K., Wenger, J., et al. Vitamin D-binding protein and vitamin D status of black Americans and white Americans. N. Engl. J. Med. 369 (2013), 1991–2000.
58. Winter, W.E., Harris, N.S., Calcium biology and disorders. Clarke, W., (eds.) Contemporary Practice in Clinical Chemistry, second ed., 2011, AACC Press, Washington, DC, 510–512.
59. Kronenberg, H.M., Hormones and disorders of mineral metabolism. Bringhurst, F.R., Demay, M.B., Larson, P.R., Kronenberg, H.M., Melmed, S., Polonsky, K.S., (eds.) William Textbook of Endocrinology, 10th ed., 2003, Saunders, Philadelphia, 1340–1341.
60. Risteli, J., Winter, W.E., Kleerekoper, M., Risteli, L., Bone and mineral metabolism. Burtis, C.A., Ashwood, E.R., Bruns, D., (eds.) Tietz Textbook of Clinical Chemistry and Molecular Diagnostics, fifth ed., 2012, Elsevier Publishing, San Diego, CA, 1738.
61. Mitlak, B.H., Daly, M., Potts, J.T. Jr., Schoenfeld, D., Neer, R.M., Asymptomatic primary hyperparathyroidism. J. Bone Miner. Res. 6 (1991), S103–S110.
62. Winter, W.E., Harris, N.S., Calcium biology and disorders. Clarke, W., (eds.) Contemporary Practice in Clinical Chemistry, second ed., 2011, AACC Press, Washington, DC, 515.
63. Martin, P., Bergmann, P., Gillet, C., Fuss, M., Corvilain, J., Van Geertruyden, J., Long-term irreversibility of bone loss after surgery for primary hyperparathyroidism. Arch. Intern. Med. 150 (1990), 1495–1497.
64. Silverberg, S.J., Gartenberg, F., Jacobs, T.P., et al. Longitudinal measurements of bone density and biochemical indices in untreated primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 80 (1995), 723–728.
65. Khosla, S., Melton, L.J. 3rd., Wermers, R.A., Crowson, C.S., O'Fallon, W., Riggs, B.I., Primary hyperparathyroidism and the risk of fracture. J. Bone Miner. Res. 14 (1999), 1700–1707.
66. Stewart, A.F., Clinical practice. Hypercalcemia associated with cancer. N. Engl. J. Med. 352 (2005), 373–379.
67. Horwitz, M.J., Hypercalcemia of malignancy. Rosen, C.J., (eds.) UpToDate, 2014, UpToDate, Waltham, MA (updated: March 13, 2014). Accessed on May 25, 2016.
68. Chen, J.D., Morrison, C., Zhang, C., Kahnoski, K., Carpenten, J.D., The, B.T., Hyperparathyroidism-jaw tumour syndrome. J. Intern. Med. 253 (2003), 634–642.
69. Hinnie, J., Bell, E., McKillop, E., Gallacher, S., The prevalence of familial hypocalciuric hypercalcemia. Calcif. Tissue Int. 68 (2001), 216–218.
70. Cali, J.P., Bowers, G.N., Young, D.S., A referee method for the determination of total calcium in serum. Clin. Chem. 19 (1973), 1208–1213.
71. Welch, M.W., Hamar, D.W., Fettman, M.J., Method comparison for calcium determination by flame atomic absorption spectrophotometry in the presence of phosphate. Clin. Chem. 36 (1990), 351–354.
72. CALCIUM oCPC [package insert], Brea, CA, Beckman Coulter Inc., 2009.
73. CALCIUM (ARSENAZO) [package insert], Brea, CA, Beckman Coulter Inc., 2009.
74. CA2 (Calcium Gen.2), Cobas system [package insert], Indianapolis, IN, Roche Diagnostics, 2012.
75. Bourguignon, C., Dupuy, A.M., Coste, T., Michel, F., Cristol, J.P., Evaluation of NM-BAPTA method for plasma total calcium measurement on Cobas 8000®. Clin. Biochem. 47 (2014), 636–639.
76. Alberti, M.O., Drake, T.A., Song, L., The pH of chemistry assays plays an important role in monoclonal immunoglobulin interferences. Pract. Lab. Med. 3 (2015), 8–16.
77. Mineral and bone metabolism. Endres, D.B., Rude, R.K., Burtis, C.A., Ashwood, E.R., Bruns, D., (eds.) Tietz Textbook of Clinical Chemistry and Molecular Diagnostics, fourth ed., 1999, Elsevier Publishing, San Diego, CA, 1900–1905.
78. Buchley, B.M., Russell, L.J., The measurement of ionized calcium in blood plasma. Ann. Clin. Biochem. 25 (1988), 447–465.
79. Toffaletti, J., Ionized calcium. Pesce, A.J., Kaplan, L.A., (eds.) Methods in Clinical Chemistry, 1987, Mosby Publishing, St. Louis, MO, 1010–1020.
80. Winter, W.E., Harris, N.S., Calcium biology and disorders. Clarke, W., (eds.) Contemporary Practice in Clinical Chemistry, second ed., 2011, AACC Press, Washington, DC, 520.
81. Razzaque, M.S., The FGF23–Klotho axis: endocrine regulation of phosphate homeostasis. Nat. Rev. Endocrinol. 5 (2009), 611–619.
82. Hu, M.C., Shi, M., Zhang, J., et al. Klotho: a novel phosphaturic substance acting as an autocrine enzyme in the renal proximal tubule. FASEB J. 24 (2010), 3438–3450.
83. Lanske, B., Razzaque, M.S., Molecular interactions of FGF23 and PTH in phosphate regulation. Kidney Int. 86 (2014), 1072–1074.
84. Bergwitz, C., Jüppner, H., Regulation of phosphate homeostasis by PTH, vitamin D, and FGF23. Annu. Rev. Med. 61 (2010), 91–104.
85. Yamashita, T., Yoshioka, M., Itoh, N., Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain. Biochem. Biophys. Res. Commun. 277 (2000), 494–498.
86. Bone and mineral metabolism. Risteli, W., Winter, M.K., Risteli, L., Burtis, C.A., Ashwood, E.R., Bruns, D., (eds.) Tietz Textbook of Clinical Chemistry and Molecular Diagnostics, fifth ed., 2012, Elsevier Publishing, San Diego, CA, 1749.
87. Daly, J.A., Ertingshausen, G., Direct method for determining inorganic phosphate in serum with the “CentrifiChem”. Clin. Chem. 18 (1972), 263–265.
88. Wheater, G., Elshahaly, M., Tuck, S.P., Datta, H.K., van Laar, J.M., The clinical utility of bone marker measurements in osteoporosis. J. Transl. Med., 11, 2013, 201.
89. Harvey, N.C., Dennison, E.M., Cooper, C., Epidemiology of osteoporotic fractures. Rosen, C.J., Compston, J.E., Lian, J.B., (eds.) Primer on the Bone Metabolic Disease and Disorders of Mineral Metabolism, seventh ed., 2008, American Society for Bone and Mineral Research, Washington, DC, 198–203.
90. Bilezikian, J.P., Rubin, M.R., Monitoring anabolic treatment. Seibel, M.J., Robin, S.P., Bilezikian, J.P., (eds.) Dynamics of Bone and Cartilage Metabolism, second ed., 2006, Academic Press, Sam Diego, CA, 629–647.
91. Szulc, P., Delmas, P., Biochemical markers on bone turnover in osteoporosis. Rosen, C.J., Compston, J.E., Lian, J.B., (eds.) Primer on the Bone Metabolic Disease and Disorders of Mineral Metabolism, seventh ed., 2008, American Society for Bone and Mineral Research, Washington, DC, 174–179.
92. Levin, A., Bakris, G.L., Molitch, M., et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int. 71 (2007), 31–38.
93. Pitts, T.O., Piraino, B.H., Mitro, R., et al. Hyperparathyroidism and 1,25-dihydroxyvitamin D deficiency in mild, moderate, and severe renal failure. J. Clin. Endocrinol. Metab. 67 (1988), 876–881.
94. Gutierrez, O., Isakova, T., Rhee, E., et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J. Am. Soc. Nephrol. 16 (2005), 2205–2215.
95. Qunibi, W.Y., Henrich, W.L., Overview of chronic kidney disease-mineral bone disease (CKD-MBD). Berns, J.S., (eds.) UpToDate, 2015, UpToDate, Waltham, MA (updated: June 17, 2015). Accessed on May 20, 2016.
96. Kooh, S.W., Fraser, D., Reilly, B.J., Hamilton, J.R., Gall, D., Bell, L., Rickets due to calcium deficiency. N. Engl. J. Med. 297 (1977), 1264–1266 Medline.
97. Maltz, H.E., Fish, M.B., Holliday, M.A., Calcium deficiency rickets and the renal response to calcium infusion. Pediatrics 46 (1970), 865–870 Abstract/free full text.
98. Legius, E., Proesmans, W., Eggermont, E., Vandamme-Lobaerts, R., Bouillon, R., Smet, M., Rickets due to dietary calcium deficiency. Eur. J. Pediatr. 148 (1989), 784–785 CrossRefMedline.
99. Pettifor, J.M., Ross, P., Wang, J., Moodley, G., Couper-Smith, J., Rickets in children of rural origin in South Africa: is low dietary calcium a factor?. J. Pediatr. 92 (1978), 320–324 CrossRefMedline.
100. Eyberg, C., Pettifor, J.M., Moodley, G., Dietary calcium intake in rural black South African children: the relationship between calcium intake and calcium nutritional status. Hum. Nutr. Clin. Nutr. 40C (1986), 69–74.
101. Pettifor, J.M., Ross, F.P., Travers, R., Glorieux, F.H., DeLuca, H.F., Dietary calcium deficiency: a syndrome associated with bone deformities and elevated serum 1,25-dihydroxyvitamin D concentrations. Metab. Bone Relat. Res. 2 (1981), 301–305.
102. Marie, P.J., Pettifor, J.M., Ross, F.P., Glorieux, F.H., Histological osteomalacia due to dietary calcium deficiency in children. N. Engl. J. Med. 307 (1982), 584–588 Medline.
103. Winter, W., Kleerekoper, M., Bone and mineral metabolism. Risteli, J., Risteli, L., Burtis, C.A., Ashwood, E.R., Bruns, D., (eds.) Tietz Textbook of Clinical Chemistry and Molecular Diagnostics, fifth ed., 2012, Elsevier Publishing, San Diego, CA, 1782–1791.
104. Seton, M., Clinical manifestations and diagnosis of Paget disease of bone. Schur, P.H., Drezner, M.K., (eds.) UpToDate, 2016, UpToDate, Waltham, MA (updated: April 19, 2016). Accessed on May 20, 2016.
105. Cavalier, E., Bergmann, P., Bruyère, O., Delanaye, P., Durnez, A., Devogelaer, J.P., Ferrari, S.L., Gielen, E., Goemaere, S., Kaufman, J.M., Toukap, A.N., Reginster, J.Y., Rousseau, A.F., Rozenberg, S., Scheen, A.J., Body, J.J., The role of biochemical of bone turnover markers in osteoporosis and metabolic bone disease: a consensus paper of the Belgian Bone Club. Osteoporos. Int. 27 (2016), 2181–2195.
106. Roodman, G.D., Mechanisms of bone metastasis. N. Engl. J. Med. 350 (2004), 1655–1664.
107. Irie, S., Hayashida, N., Shinkawa, T., Taira, Y., Sekitani, Y., Teraoka, S., Hashiguchi, K., Yoshida, K., Morishita, M., Takamura, N., Suitability of tartrate-resistant acid phosphatase type 5b as a screening marker for bone mineral density in community-dwelling elderly individuals. Tohoku J. Exp. Med. 224 (2011), 105–110.
108. Halleen, J.M., Alatalo, S.L., Suominen, H., Cheng, S., Janckila, A.J., Väänänen, H.K., Tartrate-resistant acid phosphatase 5b: a novel serum marker of bone resorption. J. Bone Miner. Res. 15 (2000), 1337–1345.
109. Arasu, A., Cawthon, P.M., Lui, L.-Y., Do, T.P., Arora, P.S., Cauley, J.A., Ensrud, K.E., Cummings, S.R., Serum sclerostin and risk of hip fracture in older Caucasian women. J. Clin. Endocrinol. Metab. 97 (2012), 2027–2032.
110. Jabbar, S., Drury, J., Fordham, J.N., Datta, H.K., Francis, R.M., Tuck, S.P., Osteoprotegerin, RANKL and bone turnover in postmenopausal osteoporosis. J. Clin. Pathol. 64 (2011), 354–357.
111. Hackl, M., Heilmeier, U., Weilner, S., Grillari, J., Circulating microRNAs as novel biomarkers for bone diseases—complex signatures for multifactorial diseases?. Mol. Cell. Endocrinol. 432 (2016), 83–95.
112. Reza, S., Shaukat, A., Mahmud, M., Arain, T.M., Umama, R., et al. Evaluation of osteopontin in combination with bone turnover markers for the assessment of osteoporosis in postmenopausal women. Br. J. Med. Med. Res. 14 (2016), 1–11.
113. Shaarawy, M., Hasan, M., Serum bone sialoprotein: a marker of bone resorption in postmenopausal osteoporosis. Scand. J. Clin. Lab. Invest. 61 (2001), 513–521.
114. Rosen, H.N., Use of biochemical markers of bone turnover in osteoporosis. Rosen, C.J., (eds.) UpToDate, 2016, UpToDate, Waltham, MA (updated: March 31, 2016). Accessed on May 14, 2016.
115. Hlaing, T.T., Compston, J.E., Biochemical markers of bone turnover—uses and limitations. Ann. Clin. Biochem. 51 (2014), 189–202.
116. Sousa, C.P., Dias, I.R., Lopez-Peña, M., Camassa, J.A., Lourenço, P.J., Judas, F.M., Gomes, M.E., Reis, R.L., Bone turnover markers for early detection of fracture healing disturbances: a review of the scientific literature. An. Acad. Bras. Cienc. 87 (2015), 1049–1061.
117. Unnanuntana, A., Gladnick, B.P., Donnelly, E., Lane, J.M., The assessment of fracture risk. J. Bone Joint Surg. Am. 92 (2010), 743–753.
118. Cosman, F., de Beur, S.J., LeBoff, M.S., Lewiecki, E.M., Tanner, B., Randall, S., Lindsay, R., Clinician's guide to prevention and treatment of osteoporosis. Osteoporos. Int. 25:10 (2014), 2359–2381.
119. Nishizawa, Y., Nakamura, T., Ohta, H., Kushida, K., Gorai, I., Shiraki, M., Fukunaga, M., Hosoi, T., Miki, T., Chaki, O., Ichimura, S., Nakatsuka, K., Miura, M., Committee on the Guidelines for the Use of Biochemical Markers of Bone Turnover in Osteoporosis Japan Osteoporosis Society, Guidelines for the use of biochemical markers of bone turnover in osteoporosis (2004). J. Bone Miner. Metab. 23 (2005), 97–104.
120. Johansson, H., Odén, A., Kanis, J.A., McCloskey, E.V., Morris, H.A., Cooper, C., Vasikaran, S., IFCC-IOF Joint Working Group on Standardisation of Biochemical Markers of Bone Turnover, A meta-analysis of reference markers of bone turnover for prediction of fracture. Calcif. Tissue Int. 94 (2014), 560–567.
121. Eastell, R., Barton, I., Hannon, R.A., et al. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J. Bone Miner. Res. 18 (2003), 1051–1056.
122. Ravn, P., Hosking, D., Thompson, D., et al. Monitoring of alendronate treatment and prediction of effect on bone mass by biochemical markers in the early postmenopausal intervention cohort study. J. Clin. Endocrinol. Metab. 84 (1999), 2363–2367.
123. Rosen, H.N., Moses, A.C., Garber, J., et al. Utility of biochemical markers of bone turnover in the follow-up of patients treated with bisphosphonates. Calcif. Tissue Int. 63 (1998), 363–368.
124. Christgau, S., Rosenquist, C., Alexandersen, P., Bjarnason, N.H., Ravn, P., Fledelius, C., Herling, C., Qvist, P., Christiansen, C., Clinical evaluation of the Serum CrossLaps One Step ELISA, a new assay measuring the serum concentration of bone-derived degradation products of type I collagen C-telopeptides. Clin. Chem. 44 (1998), 2290–2300.
125. Bauer, D.C., Black, D.M., Garnero, P., et al. Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial. J. Bone Miner. Res. 19 (2004), 1250–1258.
126. Rosen, H.N., Moses, A.C., Garber, J., et al. Serum CTX: a new marker of bone resorption that shows treatment effect more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapy. Calcif. Tissue Int. 66 (2000), 100–103 Good.
127. Vasikaran, S., Eastell, R., Bruyère, O., et al. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos. Int. 22 (2011), 391–420.
128. Vasikaran, S.D., Chubb, S.A.P., The use of biochemical markers of bone turnover in the clinical management of primary and secondary osteoporosis. Endocrine 52 (2016), 222–225.
129. Bauer, D., Krege, J., Lane, N., et al. National Bone Health Alliance Bone Turnover Marker Project: current practices and the need for US harmonization, standardization, and common reference ranges. Osteoporos. Int. 23 (2012), 2425–2433.
130. Qvist, P., Christgau, S., Pedersen, B.J., et al. Circadian variation in the serum concentration of C-terminal telopeptide of type I collagen (serum CTx): effects of gender, age, menopausal status, posture, daylight, serum cortisol, and fasting. Bone 31 (2002), 57–61.
131. Schlemmer, A., Hassager, C., Acute fasting diminishes the circadian rhythm of biochemical markers of bone resorption. Eur. J. Endocrinol. 140 (1999), 332–337.
132. Crofton, P.M., Evans, N., Taylor, M.R., Holland, C.V., Procollagen type I amino-terminal propeptide: pediatric reference data and relationship with procollagen type I carboxyl-terminal propeptide. Clin. Chem. 50 (2004), 2173–2176.
133. Glover, S.J., Eastell, R., McCloskey, E.V., Rogers, A., Garnero, P., Lowery, J., Belleli, R., Wright, T.M., John, M.R., Rapid and robust response of biochemical markers of bone formation to teriparatide therapy. Bone 45 (2009), 1053–1058.
134. Terreni, A., Pezzati, P., Biochemical markers in the follow-up of the osteoporotic patients. Clin. Cases Miner. Bone Metab. 9 (2012), 80–84.
135. Orion Diagnostica, UniQ™ P1NP RIA: Intact H-Terminal Propeptide of Type I Procollagen Radioimmunoassay Kit. http://us.idsplc.com/en-us/products/product.php?id=6309, 2008 Accessed June 8, 2016.
136. Immunodiagnosticsystems, Fully automated intact PINP. http://www.pantec.it/files/IDS-iSYS-Intact-PINP-IS-4000.pdf. Accessed 8 June 2016.
137. Roche Diagnostics. http://www.roche.com/products/product-list.htm?region=us&type=diagnostics&id=24. Accessed June 8, 2016.
138. USCN Life Science. ELISA kit. http://www.uscnk.us/elisa/ELISA-Kit-for-Human-Procollagen-I-N-Terminal-Propeptide-PINP-1354.htm. Accessed June 8 2016.
139. Koivula, M., Risteli, L., Risteli, J., Measurement of aminoterminal propeptide of type 1 procollagen (P1NP) in serum. Clin. Biochem. 45 (2012), 920–927.
140. Krege, J.H., Lane, N.E., Harris, J.M., Miller, P.D., PINP as a biological response marker during teriparatide treatment for osteoporosis. Osteoporos. Int. 25 (2014), 2159–2171.
141. Klein, G., Bodenmüller, H., Standards required for quantification of skeletal alkaline phosphatase. Clin. Chem. 42 (1996), 480–482.
142. Broyles, D.L., Nielsen, R.G., Bussett, E.M., Lu, W.D., Mizrahi, I.A., Nunnelly, P.A., Ngo, T.A., Noell, J., Christenson, R.H., Kress, B.C., Analytical and clinical performance characteristics of Tandem-MP Ostase, a new immunoassay for serum bone alkaline phosphatase. Clin. Chem. 44 (1998), 2139–2147.
143. Price, C.P., Milligan, T.P., Darte, C., Direct comparison of performance characteristics of two immunoassays for bone isoform of alkaline phosphatase in serum. Clin. Chem. 43 (1997), 2052–2057.
144. González-Calvin, J.L., Mundi, J.L., Casado-Caballero, F.J., et al. Bone mineral density and serum levels of soluble tumor necrosis factors, estradiol, and osteoprotegerin in postmenopausal women with cirrhosis after viral hepatitis. J. Clin. Endocrinol. Metab. 94 (2009), 4844–4850.
145. Confavreux, C.B., Levine, R.L., Karsenty, G., A paradigm of integrative physiology, the crosstalk between bone and energy metabolisms. Mol. Cell. Endocrinol. 310 (2009), 21–29.
146. Fukumoto, S., Martin, T.J., Bone as an endocrine organ. Trends Endocrinol. Metab. 20 (2009), 230–236.
147. Hanson, D.A., Weis, M.A., Bollen, A.M., Maslan, S.L., Singer, F.R., Eyre, D.R., A specific immunoassay for monitoring human bone resorption: quantitation of type I collagen cross-linked N-telopeptides in urine. J. Bone Miner. Res. 7 (1992), 1251–1258.
148. Blumsohn, A., Colwell, A., Naylor, K., Eastell, R., Effect of light and gamma-irradiation on pyridinolines and telopeptides of type I collagen in urine. Clin. Chem. 41 (1995), 1195–11977.
149. Clemens, J.D., Herrick, M.V., Singer, F.R., Eyre, D.R., Evidence that serum NTx (collagen-type I N-telopeptides) can act as an immunochemical marker of bone resorption. Clin. Chem. 43 (1997), 2058–2063.
150. Bonde, M., Qvist, P., Fledelius, C., Riis, B.J., Christiansen, C., Applications of an enzyme immunoassay for a new marker of bone resorption (CrossLaps): follow-up on hormone replacement therapy and osteoporosis risk assessment. J. Clin. Endocrinol. Metab. 80 (1995), 864–868.
151. Ravn, P., Clemmesen, B., Riis, B.J., Christiansen, C., The effect on bone mass and bone markers of different doses of ibandronate: a new bisphosphonate for prevention and treatment of postmenopausal osteoporosis: a 1-year, randomized, double-blind, placebo-controlled dose-finding study. Bone 19 (1996), 527–533.
152. Rosenquist, C., Fledelius, C., Christgau, S., Pedersen, B.J., Bonde, M., Qvist, P., Christiansen, C., Serum CrossLaps One Step ELISA. First application of monoclonal antibodies for measurement in serum of bone-related degradation products from C-terminal telopeptides of type I collagen. Clin. Chem. 44 (1998), 2281–2289.
153. β-CrossLaps/serum (β-CTx in serum), Cobas system [package insert]. 2015, Roche Diagnostics, Indianapolis, IN.
154. Guise, T.A., Breaking down bone: new insight into site-specific mechanisms of breast cancer osteolysis mediated by metalloproteinases. Genes Dev. 23 (2009), 2117–2123.
155. T. A. Guise, K. S. Mohammad, G. Clines, E. G. Stebbins, D. H. Wong, L. S. Higgins, R. Vessella, E. Corey, S. Padalecki, L. Suva, J. M. Chirgwin, Basic mechanisms responsible for osteolytic and osteoblastic bone metastases, Clin. Cancer Res. 12 (2006), pp. 6213s–6216s.
156. Matsumoto, T., Abe, M., Bone destruction in multiple myeloma. Ann. N.Y. Acad. Sci. 1068 (2006), 319–326.
157. Roodman, G.D., Osteoblastic function in myeloma. Bone 48 (2011), 135–140.
158. Klepzig, M., Jonas, D., Oremek, G.M., Procollagen type 1 amino-terminal propeptide: a marker for bone metastases in prostate carcinoma. Anticancer Res. 29 (2009), 671–673.
159. Klepzig, M., Sauer-Eppel, H., Jonas, D., Oremek, G.M., Value of procollagen type 1 amino-terminal propeptide in patients with renal cell carcinoma. Anticancer Res. 28 (2008), 2443–2446.
160. Koopmans, N., de Jong, I.J., Breeuwsma, A.J., van der Veer, E., Serum bone turnover markers (PINP and ICTP) for the early detection of bone metastases in patients with prostate cancer: a longitudinal approach. J. Urol. 178 (2007), 849–853.